Application of a Novel Biomarker Based on Plasma cfDNA Assay in the Early Diagnosis of Prostate Cancer

RecruitingOBSERVATIONAL
Enrollment

1,100

Participants

Timeline

Start Date

July 9, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Prostate Cancer
Interventions
DIAGNOSTIC_TEST

Blood draw

Before undergoing a prostate biopsy, participants will have about 10 mLs of venous blood drawn. Blood will be sent to Geneseeq Technology Inc. for whole genome high-throughput sequencing of plasma cfDNA.

Trial Locations (1)

201109

RECRUITING

Changzheng hospital, Shanghai

All Listed Sponsors
collaborator

Ningbo No. 1 Hospital

OTHER

collaborator

The First Affiliated Hospital of Guangzhou Medical University

OTHER

collaborator

Jiangsu Provincial People's Hospital

OTHER

collaborator

The First Affiliated Hospital of Soochow University

OTHER

collaborator

West China Hospital

OTHER

collaborator

Zhongda Hospital

OTHER

collaborator

Northern Jiangsu People's Hospital

OTHER

collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

lead

Shanghai Changzheng Hospital

OTHER